Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.280
+0.070 (5.79%)
At close: Aug 13, 2025, 4:00 PM
1.300
+0.020 (1.56%)
After-hours: Aug 13, 2025, 6:50 PM EDT
PACB Revenue
Pacific Biosciences of California had revenue of $39.77M in the quarter ending June 30, 2025, with 10.42% growth. This brings the company's revenue in the last twelve months to $156.11M, down -17.35% year-over-year. In the year 2024, Pacific Biosciences of California had annual revenue of $154.01M, down -23.19%.
Revenue (ttm)
$156.11M
Revenue Growth
-17.35%
P/S Ratio
2.39
Revenue / Employee
$271,496
Employees
575
Market Cap
384.47M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 154.01M | -46.51M | -23.19% |
Dec 31, 2023 | 200.52M | 72.22M | 56.29% |
Dec 31, 2022 | 128.30M | -2.21M | -1.69% |
Dec 31, 2021 | 130.51M | 51.62M | 65.43% |
Dec 31, 2020 | 78.89M | -12.00M | -13.20% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PACB News
- 4 days ago - Pacific Biosciences of California, Inc. (PACB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - PacBio to Present at Upcoming Investor Conferences - GlobeNewsWire
- 9 days ago - Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models - GlobeNewsWire
- 15 days ago - Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing - PRNewsWire
- 20 days ago - PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications - GlobeNewsWire
- 21 days ago - PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio - GlobeNewsWire
- 23 days ago - PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 2 months ago - Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date - PRNewsWire